AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis as a treatment for a type of lung cancer. The US regulator cleared Emrelis ...
It’s been almost a decade since Japanese pharma company Daiichi Sankyo began its dramatic pivot from cardiovascular health into antibody-drug conjugates. For Daiichi Sankyo, it’s hard to argue that ...
The role of inflammatory monocytes in human metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2015 Gastrointestinal Cancers Symposium. This abstract does not include a full text ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results